Research Progress on Disulfide-mediated Cell Death in 
Gliomas

Jingxian Zhang; Yajia Chen; Hongwu Xu*

doi:10.70711/mhr.v2i4.5499

Research Progress on Disulfide-mediated Cell Death in Gliomas

Jingxian Zhang, Yajia Chen, Hongwu Xu*

Abstract

Glioma is a highly invasive brain tumor, and its treatment has always been a major challenge in clinical practice. In recent years,
disulfide death, as a novel mechanism of cell death, has attracted widespread attention. This article reviews the biological basis, molecular
mechanisms, and potential applications of disulfide-mediated cell death in the treatment of glioblastoma. By analyzing the induction mechanism and therapeutic effect of disulfide-mediated cell death in glioma cells, the prospects and possible treatment strategies for disulfide-mediated cell death in glioma treatment were explored. This article aims to provide a new theoretical basis and research directions for the treatment
of glioma.

Keywords

Disulfide death; Glioma; Cell death mechanism

Full Text:

PDF

Included Database

References

StatPearls Publishing LLC.; 2022.

[2] Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ: Exciting new advances in neuro-oncology: the avenue to a

cure for malignant glioma. CA: a cancer journal for clinicians 2010, 60(3): 166-193.

[3] Wesolowski JR, Rajdev P, Mukherji SK: Temozolomide (Temodar). AJNR American journal of neuroradiology 2010, 31(8): 1383-

1384.

[4] Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF: A restricted cell population propagates glioblastoma growth

after chemotherapy. Nature 2012, 488(7412): 522-526.

[5] Snyder AG, Oberst A: The Antisocial Network: Cross Talk Between Cell Death Programs in Host Defense. Annual review of immunology 2021, 39: 77-101.

[6] Peng F, Liao M, Qin R, Zhu S, Peng C, Fu L, Chen Y, Han B: Regulated cell death (RCD) in cancer: key pathways and targeted

therapies. Signal transduction and targeted therapy 2022, 7(1): 286.

[7] Tong X, Tang R, Xiao M, Xu J, Wang W, Zhang B, Liu J, Yu X, Shi S: Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. Journal of hematology & oncology 2022, 15(1): 174.

[8] Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A: Glioblastoma: pathology, molecular mechanisms and markers.

Acta neuropathologica 2015, 129(6): 829-848.

[9] Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison

DW: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta neuropathologica 2016, 131(6): 803-820.

[10] Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G et al: The

2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-oncology 2021, 23(8): 1231-1251.

DOI: http://dx.doi.org/10.70711/mhr.v2i4.5499

Refbacks

There are currently no refbacks.